PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Research Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, 211166, Jiangsu, China.\', \'Department of Bioinformatics, Nanjing Medical University, 101 Longmian Avenue, Jiangning District, Nanjing, 211166, Jiangsu, China.\', \'Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.\', \'Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing, 211166, Jiangsu, China.\', \'The Affiliated Cancer Hospital and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, China.\', \'Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, China.\', \'Research Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, 211166, Jiangsu, China. wangqh@njmu.edu.cn.\', \'Department of Bioinformatics, Nanjing Medical University, 101 Longmian Avenue, Jiangning District, Nanjing, 211166, Jiangsu, China. wangqh@njmu.edu.cn.\', \'Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China. wangqh@njmu.edu.cn.\', \'Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing, 211166, Jiangsu, China. wangqh@njmu.edu.cn.\', \'COVID-19 Research Center, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing Clinical College of Southern Medical University, Nanjing, 210002, Jiangsu, China. xinyixia@nju.edu.cn.\', \'Joint Expert Group for COVID-19, Department of Laboratory Medicine and Blood Transfusion, Wuhan Huoshenshan Hospital, Wuhan, 430100, Hubei, China. xinyixia@nju.edu.cn.\', \'Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China. sk_wang@njmu.edu.cn.\', \'Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, Jiangsu, China. sk_wang@njmu.edu.cn.\', \'Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China. lvling@njmu.edu.cn.\', \'The Affiliated Cancer Hospital and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, China. lvling@njmu.edu.cn.\', \'Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, China. lvling@njmu.edu.cn.\', \'State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, China. lvling@njmu.edu.cn.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1007/s12072-020-10123-0
?:hasPublicationType
?:journal
  • Hepatology international
is ?:pmid of
?:pmid
?:pmid
  • 33548030
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.042
?:rankingScore_hIndex
  • 36
is ?:relation_isRelatedTo_publication of
?:title
  • Implications of liver injury in risk-stratification and management of patients with COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all